BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and Trademark Office (USPTO) has granted BioArctic a new platform patent for a technology for transporting biopharmaceuticals across the blood-brain barrier. The patent, which is part of the company’s Brain Transporter patent portfolio, will take effect on November 15, 2022, and expire in 2037.
The blood-brain barrier protects the brain from foreign substances by restricting the passage of these substances into the brain. The patented technology (US patent no. 11,498,974) has been developed to facilitate the transport of biopharmaceuticals across this barrier, thereby potentially improving drug efficacy.
“We are pleased that the US Patent and Trademark Office has granted this new patent. Improved transportation of biopharmaceuticals across the blood-brain barrier may lead to improved efficacy and reduced side-effects in current and future treatments of brain disorders,” says Gunilla Osswald, CEO, BioArctic.
The information was released for public disclosure, through the agency of the contact persons below, on November 14, 2022, at 08:00 a.m. CET.
